APA (7th ed.) Citation

F, S., BE, M., S, S., F, G., L, M., L, E., . . . HH, O. (2022). Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies. Toxicology and applied pharmacology, 434, 115796. https://doi.org/10.1016/j.taap.2021.115796

Chicago Style (17th ed.) Citation

F, Salinas, et al. "Non-clinical Safety Assessment and in Vivo Biodistribution of CoviFab, an RBD-specific F(ab')2 Fragment Derived from Equine Polyclonal Antibodies." Toxicology and Applied Pharmacology 434 (2022): 115796. https://doi.org/10.1016/j.taap.2021.115796.

MLA (9th ed.) Citation

F, Salinas, et al. "Non-clinical Safety Assessment and in Vivo Biodistribution of CoviFab, an RBD-specific F(ab')2 Fragment Derived from Equine Polyclonal Antibodies." Toxicology and Applied Pharmacology, vol. 434, 2022, p. 115796, https://doi.org/10.1016/j.taap.2021.115796.